Nisa Investment Advisors LLC lessened its position in Surmodics, Inc. (NASDAQ:SRDX - Free Report) by 98.4% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,093 shares of the company's stock after selling 67,336 shares during the period. Nisa Investment Advisors LLC's holdings in Surmodics were worth $42,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds also recently made changes to their positions in SRDX. Acadian Asset Management LLC raised its position in Surmodics by 11.3% in the 1st quarter. Acadian Asset Management LLC now owns 408,779 shares of the company's stock valued at $11,988,000 after purchasing an additional 41,617 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of Surmodics by 5.0% in the second quarter. Renaissance Technologies LLC now owns 606,538 shares of the company's stock valued at $25,499,000 after buying an additional 28,990 shares in the last quarter. Gardner Lewis Asset Management L P bought a new position in shares of Surmodics in the second quarter valued at about $8,531,000. Sagefield Capital LP acquired a new position in Surmodics during the 2nd quarter worth about $2,350,000. Finally, Trium Capital LLP bought a new stake in Surmodics during the 2nd quarter worth about $1,406,000. Institutional investors and hedge funds own 96.63% of the company's stock.
Surmodics Trading Up 0.2 %
Surmodics stock traded up $0.06 during trading hours on Friday, reaching $38.46. 118,959 shares of the company's stock traded hands, compared to its average volume of 230,828. The firm has a market capitalization of $548.82 million, a price-to-earnings ratio of -47.48 and a beta of 1.20. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.22 and a current ratio of 3.98. Surmodics, Inc. has a fifty-two week low of $25.17 and a fifty-two week high of $42.44. The firm's 50 day moving average is $38.57 and its 200-day moving average is $38.77.
Analyst Ratings Changes
A number of equities analysts have weighed in on SRDX shares. StockNews.com started coverage on shares of Surmodics in a research note on Thursday. They issued a "hold" rating for the company. Needham & Company LLC reissued a "hold" rating on shares of Surmodics in a report on Thursday. Five research analysts have rated the stock with a hold rating, According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $50.00.
Get Our Latest Analysis on Surmodics
Surmodics Profile
(
Free Report)
Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).
See Also
Before you consider Surmodics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Surmodics wasn't on the list.
While Surmodics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
